Vanda stalls in EU with Fanaptum
This article was originally published in Scrip
Executive Summary
Vanda Pharmaceuticals has withdrawn its marketing authorisation application (MAA) for its atypical antipsychotic, Fanaptum (oral iloperidone tablets) for schizophrenia, despite last month requesting a re-examination of a negative decision by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on the drug.